|
Aducanumab is the given USAN and INN name for a biopharmaceutical, the human monoclonal antibody and drug candidate BIIB0307 designed for treatment of Alzheimer's disease (AD).〔Cynthia Fox for Drug Discovery and Development. April 28, 2015 〕 == References == 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Aducanumab」の詳細全文を読む スポンサード リンク
|